선택적 B-RAF V600E 억제제 PLX4032에 의한 유방암 세포주에서의 세포주기 억제
Selective B-RAF V600E Inhibitor PLX4032 Inhibits the Growth of Breast Cancer Cell Lines through Cell Cycle Arrest
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Breast cancer is the most common invasive cancer and the second common cause of death among women worldwide. Many researchers have focused on the effective treatment of advanced breast cancer using new drugs. Herein, we analyzed whether PLX4032, a B-RAF V600E inhibitor, could be used as a novel treatment for advanced breast cancer. Methods: Two breast cancer cell lines, MCF7 and MDA-MB-231, were treated with the selective B-Raf inhibitor PLX4032 under adherent culture conditions and the effects of PLX4032 on cell growth, cell cycle duration, apoptosis and cell cycle related genes expression were evaluated. Results: We found that PLX4032 dose-dependently inhibited cell growth in both cell lines through cell cycle arrest at phase G0/G1. However, PLX4032 treatment did not have a significant effect on cell apoptosis. In addition, CCNA2 gene expression was significantly decreased in the MCF7 cells in a dose-dependent manner. Conclusion: Our data demonstrated that treatment of breast cancer with PLX4032 could inhibit proliferation through cell cycle arrest. Therefore, PLX4032 might be a novel anticancer drug that can be used in the treatment of advanced breast cancer.
Abstract
Purpose: Breast cancer is the most common invasive cancer and the second common cause of death among women worldwide. Many researchers have focused on the effective treatment of advanced breast cancer using new drugs. Herein, we analyzed whether PLX4032, a B-RAF V600E inhibitor, could be used as a novel treatment for advanced breast cancer. Methods: Two breast cancer cell lines, MCF7 and MDA-MB-231, were treated with the selective B-Raf inhibitor PLX4032 under adherent culture conditions and the effects of PLX4032 on cell growth, cell cycle duration, apoptosis and cell cycle related genes expression were evaluated. Results: We found that PLX4032 dose-dependently inhibited cell growth in both cell lines through cell cycle arrest at phase G0/G1. However, PLX4032 treatment did not have a significant effect on cell apoptosis. In addition, CCNA2 gene expression was significantly decreased in the MCF7 cells in a dose-dependent manner. Conclusion: Our data demonstrated that treatment of breast cancer with PLX4032 could inhibit proliferation through cell cycle arrest. Therefore, PLX4032 might be a novel anticancer drug that can be used in the treatment of advanced breast cancer.
참고문헌 (19)
- 정규원, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2012", Cancer Research and Treatment, 47(2), pp.127~141 (2015), 대한암학회[DOI]
- Zuckerman JE, "siRNA knockdown of ribonucleotide reductase inhibits melanoma cell line proliferation alone or synergistically with temozolomide", J Invest Dermatol, 131, pp.453~460 (2011)
- Gril B, "The B-Raf status of tumor cells may be a significant determinant of both antitumor and anti-angiogenic effects of pazopanib in xenograft tumor models", PLoS One, 6, pp.e25625~ (2011)
- Zustiak SP, "The role of matrix compliance on cell responses to drugs and toxins: towards predictive drug screening platforms", Macromol Biosci, 15, pp.589~599 (2015)
- Al-Suwaidan IA, "Antitumor evaluation and molecular docking study of substituted 2-benzylidenebutane-1,3-dione, 2-hydrazonobutane-1,3-dione and trifluoromethyl-1H-pyrazole analogues", J Enzyme Inhib Med Chem, 30, pp.679~687 (2015)
- Enthammer M, "Isolation of a novel thioflavin S-derived compound that inhibits BAG-1-mediated protein interactions and targets BRAF inhibitor-resistant cell lines", Mol Cancer Ther, 12, pp.2400~2414 (2013)
- Plotnikov A, "The nuclear translocation of ERK1", 2 as an anticancer target, 2015, pp.6, 6685~
- Jiao Y, "Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents", Eur J Med Chem, 90, pp.170~183 (2015)
- Al-Suwaidan IA, "Synthesis, antitumor activity and molecular docking study of some novel 3-benzyl-4(3H)quinazolinone analogues", J Enzyme Inhib Med Chem, 31, pp.78~89 (2016)
- Lee JT, "PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas", Pigment Cell Melanoma Res, 23, pp.820~827 (2010)
- Søndergaard JN, "Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032", J Transl Med, 8, pp.39~ (2010)
- Sala E, "BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells", Mol Cancer Res, 6, pp.751~759 (2008)
- Yang H, "RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models", Cancer Res, 70, pp.5518~5527 (2010)
- Salerno P, "Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells", J Clin Endocrinol Metab, 95, pp.450~455 (2010)
- Niehr F, "Combination therapy with vemurafenib (PLX4032", RG7204) and metformin in melanoma cell lines with distinct driver mutations, 2011, pp.9, 76~
- Dummer R, "Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study", Eur J Cancer, 50, pp.611~621 (2014)
- Garay JP, "The growth response to androgen receptor signaling in ERalpha-negative human breast cells is dependent on p21 and mediated by MAPK activation", Breast Cancer Res, 14, pp.R27~ (2012)
- De Roock W, "Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis", Lancet Oncol, 11, pp.753~762 (2010)
- Choi J, "Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors", Pigment Cell Melanoma Res, 27, pp.253~262 (2014)